Acesso livre
Acesso livre

Alergia e Imunologia

Estudo compara a queda da efetividade das vacinas da Moderna, da Pfizer e da Janssen, além das consequências para a mortalidade.

5 Nov, 2021 | 17:21h

Estudo original: SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 – Science

Comunicado de imprensa: Breakthrough Infection Study Compares Decline in Vaccine Effectiveness and Consequences for Mortality – Public Health Institute

 

Comentário no Twitter

 

Diretriz do CDC | Pessoas imunocomprometidas podem precisar de uma quarta dose de vacina contra Covid-19.

4 Nov, 2021 | 12:05h

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States – Centers for Disease Control and Prevention

Comentários:

Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN

Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News

Dez coisas a saber sobre a síndrome inflamatória multissistêmica em crianças (multisystem inflammatory syndrome in children – MIS-C).

4 Nov, 2021 | 12:01h

Ten Things to Know About MIS-C – American College of Cardiology

Conteúdos relacionados:

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

M-A | Zinco pode ajudar a cessar os sintomas de infecção respiratória e encurtar a duração da doença – “Contudo, a qualidade da evidência é variável, e não há clareza sobre uma formulação ou uma dose ótimas.”

4 Nov, 2021 | 11:54h

Comunicado de imprensa: Zinc might help to stave off respiratory infection symptoms and cut illness duration – BMJ

Estudo original: Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials – BMJ Open

 

Comentário no Twitter

 

Entre as pessoas vacinadas contra Covid-19, aquelas com infecção prévia tendem a produzir mais anticorpos.

2 Nov, 2021 | 12:38h

Comunicado de imprensa: In Covid-19 Vaccinated People, Those with Prior Infection Likely to Have More Antibodies – Johns Hopkins Medicine

Artigo original: Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection – JAMA

Estudo do CDC | Vacina contra COVID-19 está associada com proteção 5 vezes maior que a “imunidade natural”.

1 Nov, 2021 | 10:59h

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021 – CDC Morbidity and Mortality Weekly Report

Comentários:

COVID-19 vaccine gives 5 times the protection of ‘natural immunity,’ data show – CIDRAP

COVID shots more protective than past infection, study shows – Associated Press

 

Comentário no Twitter

 

Vacinas de mRNA induzem memória imunológica durável contra SARS-CoV-2 e variantes de preocupação.

29 Out, 2021 | 14:53h

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern – Science

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

Covid-19 em indivíduos já vacinados ocorre com mais frequência naqueles com baixos níveis de anticorpos.

27 Out, 2021 | 12:42h

Breakthrough Infections Occur in Those with Lower Antibody Levels, Israeli Study Shows – NIH Director’s Blog

Estudo original: Covid-19 Breakthrough Infections in Vaccinated Health Care Workers – New England Journal of Medicine

Vacinação heteróloga AstraZeneca/Pfizer parece estar associada com maior efetividade contra Covid-19 em comparação com a vacinação homóloga Pfizer/Pfizer.

27 Out, 2021 | 12:41h

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination – Nature

Conteúdos relacionados:

Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.

Should You Mix and Match Your Booster Shot?

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

 

Diferentes vacinas contra COVID misturadas e combinadas com sucesso no teste de efetividade – “Não é preciso se restringir a nenhuma marca.”

27 Out, 2021 | 12:39h

Mix-and-match COVID vaccines ace the effectiveness test – Nature

Conteúdos relacionados:

Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.

Should You Mix and Match Your Booster Shot?

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.